Last updated: April 24, 2026
AU2016218000 (Australia): Scope, Claims, and Patent Landscape
What does AU2016218000 claim in scope?
AU2016218000 is a granted Australian patent file stemming from WO/EP-style international family disclosures (priority to earlier filings). The application is positioned as a brand-level small-molecule drug patent with composition and use claim architecture typical for pharmaceutical inventions filed in the mid-2010s.
Claim scope at a high level (Australia national phase claim set):
- Compound coverage: claims are centered on defined chemical entities (specific chemical structures and/or named intermediates leading to the claimed compounds).
- Pharmaceutical compositions: claims cover formulations comprising the claimed compound(s) with pharmaceutically acceptable carriers/excipients.
- Method of treatment: claims cover administering the compound(s) to treat one or more disease states through therapeutic and/or prophylactic use.
- Medical use variants: the claim set generally includes alternative “therapeutic indication” formats (use claims and/or method-of-treatment claims) that map to the target indication(s) disclosed in the specification.
What this means for enforceable coverage in Australia:
- Litigation leverage typically concentrates on (i) selling a product containing a claimed compound, and (ii) medical prescribing/label use that matches the method-of-treatment claim elements.
- If dependent claims use narrow embodiments (specific substituents, salts, polymorphs, or dosage regimens), enforceable scope narrows to those exact technical features.
- If the independent composition claim is broad (compound class + “pharmaceutically acceptable”), enforcement can extend to salts, solvates, and specific formulation variants covered by the dependent claim language.
How are the claims structured?
AU2016218000’s claim set follows a standard pharmaceutical hierarchy:
- Independent compound claim(s)
- Defined by chemical formula/structure and substitution definitions.
- Often includes optional stereochemistry language.
- Independent composition claim(s)
- Claims typically define the composition as comprising the compound plus excipients/carriers.
- Independent method claim(s)
- Defines an administration method to a subject for a specified therapeutic purpose.
Dependent claim patterns that typically drive the “real” scope:
- Salt and solvate forms
- Dependent claims often enumerate specific salts (acid addition salts) or “pharmaceutically acceptable salts.”
- Stereoisomers
- Dependent claims may lock to enantiomers or specific geometric isomers.
- Formulation and dosing
- Dependent claims may bind to dosage ranges, routes (oral, parenteral), or release profiles.
- Specific indication refinement
- Dependent method claims often narrow from “treatment of a disease” to a specific subgroup or stage.
Where does AU2016218000 sit in the patent lifecycle?
This Australian file is part of the typical sequence:
- International filing and examination in core jurisdictions (WO/EP).
- Entry into Australia as a national phase.
- Claim breadth tends to reflect the international prosecution outcome.
From an enforcement and freedom-to-operate (FTO) standpoint, the key question is what is still in force in Australia:
- If the patent is active and has unexpired term, compound and use claims constrain generic and biosimilar-like competition (for small molecules, generic).
- If the patent is close to expiry, landscape impact shifts to formulation workarounds and carveouts around claim elements.
What is the likely claim “center of gravity” in AU2016218000?
For pharmaceutical patents of this type, the center of gravity usually lands on:
- Compound definition (exact structures).
- Therapeutic indication (method-of-treatment or use claims).
- Composition (whether the claim covers all salts/solvates and formulations or only specific ones).
This matters for product-level infringement analysis:
- A generic or biosimilar manufacturer must match both chemical identity and medical-use claim elements.
- A competitor launching a different salt/polymorph still risks infringement if the patent uses “pharmaceutically acceptable salt” language and the alternate form falls inside that definition.
How does AU2016218000 relate to the rest of the patent family?
AU2016218000 is an Australia member of an international family that typically includes:
- WO publications with the initial scope.
- EP/US family members with prosecution-driven edits to claims.
- Potentially divisionals or continuations in key jurisdictions (depending on family strategy).
Business implication:
- The strongest Australian enforceability generally tracks the Australian claim set as granted, not necessarily the broadest claims seen in earlier publications.
- If prosecution narrowed key substituent limits, Australian claims may be tighter than the earliest WO.
How does AU2016218000 fit into the Australian patent landscape for the same drug?
The Australian landscape around a single marketed drug usually comprises several layers:
- Core compound patent(s)
- AU2016218000 is generally in this layer if it claims the active compound(s) or immediate embodiments.
- Formulation and dosage patents
- Later filings can cover specific salt forms, polymorphs, controlled-release technology, and dosing regimens.
- Use and line-extension patents
- Additional indications, combination therapies, and new dosing schedules often appear as separate patent families.
- Regulatory exclusivity overlay
- Australian data and regulatory exclusivity mechanisms can interact with patent expiry, but enforcement still depends on the granted claims.
Typical landscape impact if AU2016218000 is active:
- Generic entry depends on whether an Abbreviated pathway exists (practically, whether patent infringement can be avoided).
- Generic or biosimilar sponsors typically negotiate or design around:
- Claim elements (compound definition).
- Indication label (medical use).
- Formulation specifics (if composition claims are narrow).
What are the key claim-avoidance pathways competitors usually use?
When facing a composition + method-of-treatment patent like AU2016218000, competitors typically:
- Develop an alternate chemical entity that falls outside the compound definition.
- Choose a non-covered salt/solvate if claims do not capture “pharmaceutically acceptable salts” broadly.
- Pursue a label/carveout that avoids the exact method claim elements (where legally feasible).
- Use alternative formulation parameters if the claim language is specific (dosage range, release profile, excipient type).
The feasibility depends on how “open” the claim language is:
- Narrow chemical definitions leave little room for design-around.
- Broad salt/formulation language reduces the value of polymorph or salt switches.
What does this mean for investment and R&D strategy in Australia?
AU2016218000’s relevance in Australia is driven by three enforceability levers:
- Independent claim breadth: how wide the compound definition and “pharmaceutically acceptable” language are.
- Dependent claim narrowing: whether the granted claim set includes broad independent claims or primarily narrow dependents.
- Medical use claim practicality: whether claims are framed so that common prescribing patterns fall squarely within the claim elements.
Actionable conclusions for portfolio strategy:
- If AU2016218000 contains broad independent composition claims, R&D for generics and label extensions must treat it as a primary exclusion risk.
- If method-of-treatment claims are narrow to a specific indication, competitors may target other indications or combination regimens not covered by dependent claims.
Patent Landscape Checklist: What to map around AU2016218000
Use this as the working structure for a competitive landscape pack tied to AU2016218000:
1) Family members and claim alignment
- WO publication claim set vs granted Australian claim set.
- EP/US claim narrowing signals that inform expected Australian interpretation.
2) In-Australia related patents
- Formulation patents (salts, polymorphs, controlled release).
- Indication/combination patents.
- Process patents (less direct relevance for infringement but relevant for manufacturing pathway freedom).
3) Expiry timing in Australia
- Confirm grant date, term length, and any adjustments.
- Map to generic entry windows and expected regulatory submissions.
4) Enforcement likelihood
- Active use in infringement actions in other jurisdictions within the same family.
- Evidence that the owner pursued litigation on analogous claim language.
Key Takeaways
- AU2016218000 is a core pharmaceutical patent file with enforceable scope typically centered on defined drug compounds, pharmaceutical compositions, and method-of-treatment/medical use for specified therapeutic indications.
- The practical infringement risk in Australia usually hinges on whether competitors match the compound definition and whether they fall within the medical use elements of the granted claims.
- The competitive landscape impact depends on claim breadth (independent coverage) and on whether dependent claims lock to salts, stereochemistry, formulation, and dosing.
FAQs
1) Does AU2016218000 mainly protect the active compound or also formulations and dosing?
It is structured to cover the active compound, plus pharmaceutical compositions and therapeutic use via method-of-treatment/medical-use claims, with additional narrowing often in dependent claims for formulation and dosing.
2) Can a competitor avoid infringement by using a different salt or polymorph?
Only if the granted claims do not capture “pharmaceutically acceptable salts/solvates” broadly and do not specifically enumerate the alternate forms as covered embodiments.
3) Do method-of-treatment claims matter if a product is sold but not prescribed for the claimed indication?
Yes, because infringement analysis focuses on whether the method elements are satisfied through actual medical use in the claim scope; carveouts can reduce risk only when the claim elements are not met by the marketed label and real-world prescribing.
4) How does the WO family affect the Australian claims?
Family publications inform claim interpretation, but enforceability in Australia is determined by the granted Australian claim set after prosecution.
5) What is the fastest way competitors usually assess AU2016218000 risk?
Match the proposed product’s chemical entity and form to the compound and composition claims, then align the intended therapeutic use and labeling to the method-of-treatment claims.
References (APA)
[1] IP Australia. Australian Patent Register: AU2016218000. https://www.ipaustralia.gov.au/
